What India’s HPV Vaccine Rollout Invites Us to Ask
On February 28, 2026, India launched free HPV vaccination for 14-year-old girls nationwide — a single dose aimed at preventing cervical cancer, a disease that kills tens of thousands of Indian women every year. It is a genuine public health milestone. The policy is also careful, on paper, about consent: a dose cannot be given until a parent or guardian has agreed, and that agreement is meant to be recorded on the U-WIN digital platform, or on paper where connectivity does not allow it.
This brief looks at one question the rollout raises: what would it mean to also bring the girl herself into that conversation?
A Voice Worth Adding
She is 14. Old enough to be in Class 9, to sit for board exams, to hold opinions about her own future. She may have heard of cervical cancer, may even have a mother or aunt who lived through it. She may also simply be nervous, and have questions she would like answered before a needle goes into her arm.
In practice, she is rarely asked directly. An ASHA worker brings her to the health centre, she is registered on a digital platform she may not know exists, and she is vaccinated, to protect her.
Medicine has a useful concept here: assent. Distinct from legal consent, which rests with a parent, assent is a child’s own affirmative agreement to a procedure. It recognises that even a girl who cannot legally consent still deserves to be informed, to ask questions, and to have her hesitation taken seriously. The difference is between a child who complies and one who genuinely participates in a decision about her own body. India’s programme does not currently build this in: there is no requirement that a girl be spoken to, told what the vaccine does, or have her questions recorded. Adding that piece seems worth exploring.
What We’re Seeing on the Ground
Field reports and media coverage from one of the pilot states, describe girls being registered and vaccinated with an ASHA worker or NGO staff beside them, but often without a parent physically present or reachable by phone at that moment. Two separate, and quite fixable, questions sit inside this observation.
The first is about timing. The current system asks a parent to confirm consent by phone (a one-time code, or OTP) at registration, sometimes days before the actual vaccination. Confirming consent once, in advance, is not quite the same as a parent knowingly saying yes at the moment the injection happens. This can be addressed without any new law; it mainly needs a shift in what counts as “consent completed.”
The second is about reach. The phone-code system assumes reliable network access and a phone the parent can get to quickly. These assumptions do not always hold in rural Indian contexts. In another state, the same requirement left health workers unable to vaccinate girls whose parents’ codes never arrived, leaving hundreds of thousands of doses unused in cold storage. Some states have responded by moving to an “opt-out” approach, where consent is assumed unless a parent actively objects — which solves the logistics problem but loosens the very safeguard the phone code was meant to provide. This is worth pausing on before it becomes the default fix, since offline alternatives (a recorded phone call, a witnessed paper form) could preserve an active “yes” without depending on network signal.
What Other Health Systems Do
Other countries have already worked through versions of this question. England has used something called Gillick competence since 1985, where a health worker judges, case by case, whether a young person understands a procedure well enough to have a say in it, which is now a routine part of adolescent care. A 2024 study of an HPV vaccine trial in Tanzania adapted a lighter version for a lower-resource setting: parental consent still stands, but a trained worker also sits with the child separately, explains the vaccine, and notes whether she agrees. Both approaches move the decision through the family rather than past the girl entirely, and neither requires new legislation, just a short conversation, and somewhere to record the answer.
Ideas Worth Piloting: Implementing Organisations
State health departments, NGOs, and ASHA training bodies could consider:
• Confirming consent at the moment of vaccination, not only at registration, a brief phone check or a parent present at the time of injection.
• Piloting a short, two-minute assent conversation for girls 12 and older, where a trained worker explains the vaccine and asks directly whether she is willing, logging her answer.
• Equipping ASHAs with a simple, local-language card on side effects , ie. soreness, mild fever, occasional dizziness, so every family hears the same clear information, regardless of how rushed the day is.
• Holding a consent conversation at the block level, before the vaccination team arrives, bringing parents, panchayat representatives, and the girls themselves into the same room ahead of time.
• Making “not today” a genuinely easy option at every site, one that does not count against a health worker’s numbers.
• Strengthening how the vaccine itself is explained: clear, science-based communication on why it was chosen, what it protects against, and its limitations. This will include addressing common concerns directly so families are making a genuinely informed choice.
Ideas Worth Piloting: Policymakers
Union and State Health Ministries could consider:
• A written definition of “informed consent” for non-trial immunisation, giving implementing organisations a stable target to train toward.
• Exploring offline alternatives that preserve an active yes before an opt-out model becomes the standard answer to the OTP problem.
• Once piloted, making assent a required field in U-WIN for girls 12 and up, turning a good local practice into a consistent national one.
• Reviewing ASHA and ANM incentive structures, to ensure frontline workers are never better off, financially or administratively, when a family’s hesitation is overridden rather than respected.
Protection and Participation, Together
The HPV vaccine is a scientific triumph, and offering it free to every 14-year-old girl in India is a genuine milestone in public health. Preventing a cancer that often arrives without warning is as close to a gift as medicine offers.
How that gift reaches her matters too. Ethically, because she has a right to understand what is happening to her own body; practically, because trust, once shaken, is hard to rebuild; and over the long run, because this shapes how India’s youngest citizens come to see the state’s care for them.
The girl at the centre of this programme is old enough to understand and, right now, young enough to be left out of the conversation. Bringing her in is a small addition to a very large and worthwhile programme and one well within reach.
